liposomal doxorubicin market cover

Liposomal Doxorubicin Market Applications (Ovarian Cancer, Liver Cancer, Gastric Cancer, Kidney Cancer, Endometrial Cancer, Breast Cancer, Bone Sarcoma, Multiple Myeloma, Kaposi Sarcoma, Lukemia, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: CG-2492
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global liposomal doxorubicin market size was valued at USD 1.08 billion in 2020 and is anticipated to expand at a substantial CAGR during the forecast period, 2021-2028. The growth of the market is due to the increasing incidence of ovarian & breast cancer. Increasing awareness among the people regarding advantages of liposomal doxorubicin formulation over the traditional doxorubicin presents another major factor for the overall market growth.

liposomal doxorubicin market summary

Liposomal doxorubicin is a type of chemotherapy medication used for the treatment of several types of cancer including ovarian cancer, blood cancer, and others. As per the statistics by the National Cancer Institute (NCI), 1,762,450 new cancer cases of the disease and 606,880 deaths were reported due to cancer in 2019. The mortality rate is expected to increase rapidly in the coming years due to high prevalence of cancer globally. It was also reported that nearly 15,270 adolescents and children between the ages of one to 19 were diagnosed with cancer in 2017 among which 1,790 death cases were recorded regarding the same.

Branded liposomal doxorubicin named doxil or caelyx are widely applied for the treatment of ovarian cancer and other several types of cancer. However, due to the lack of easy availability of these drugs, a general version of liposomal doxorubicin formulation was approved by the U.S. Food and Drug Administration (FDA) for the treatment of second-line cancer of various types. The market growth is further accelerated due to increasing demand for this particular drug, which also leads to massive import of doxorubicin HCl liposome injections.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing number of companies for the manufacturing of liposomal doxorubicin is anticipated to fuel the market growth during the forecast period.
  • Wide development & launch of generic form of liposomal doxorubicin formulation is expected to propel the market growth in the coming years.
  • Wide prevalence of cancer globally and an increase in the application of liposomal doxorubicin for the treatment of cancer are estimated to drive the market expansion.
  • Side effects caused due to usage of liposomal doxorubicin formulation are key challenges that can restrain the market growth in the coming years.
  • Ongoing research & development programs for the advancement of technologies are projected to create profitable opportunities for the market during the forecast period.

Scope of the Report

The report on the global liposomal doxorubicin market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Liposomal Doxorubicin Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Myocet, Lipodex, Doxil/Caelyx, and Others) and Applications (Ovarian Cancer, Liver Cancer, Gastric Cancer, Kidney Cancer, Endometrial Cancer, Breast Cancer, Bone Sarcoma, Multiple Myeloma, Kaposi Sarcoma, Lukemia, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson; Sun Pharmaceutical Industries Ltd.; Merck & Co.; Cadila Pharmaceuticals; Cipla, Inc.; and SRS Pharmaceuticals Pvt. Ltd.

Market Segment Insights

Doxil/Caelyx segment is expected to dominate the market

On the basis of products, the global liposomal doxorubicin is divided into myocet, lipodex, doxil/caelyx, and others. The doxil/caelyx segment is expected to dominate the market during the targeted period attributed to its increasing demand for the second-line treatment of ovarian cancer. On the other hand, the others segment is expected to grow at a fast rate in the coming years due to the increasing number of approvals granted to generic drugs that can be used when there is a shortage of life-saving drugs. The increasing availability of products including DOXT SL tablets, nudoxa injections, and evacet is another factor expected to drive the market segment growth. However, the lack of granting of approval for products except for lipodox and doxil is expected to have a negative impact on the market.

liposomal doxorubicin market type

Breast cancer segment is anticipated to grow at a considerable rate

Based on applications, the market is segmented into ovarian cancer, liver cancer, gastric cancer, kidney cancer, endometrial cancer, breast cancer, bone sarcoma, multiple myeloma, kaposi sarcoma, lukemia, and others. The breast cancer segment held a key share of the market and is anticipated to grow at a considerable rate during the forecast period attributed to increasing advancement in the formulation. The breast cancer segment is followed by ovarian cancer and is anticipated to grow at a significant rate owing to the rising demand for drugs for targeted therapy and the growing usage of chemotherapy drugs. On the other hand, the liver cancer segment is estimated to exhibit a high growth rate during the forecast period owing to the fact that liposomal doxorubicin is proved to be the most effective chemotherapeutic drug for hepatocellular carcinoma.

Asia Pacific is expected to expand at a profitable rate

In terms of regions, the global liposomal doxorubicin market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large share of the market in 2019 and is projected to register a substantial CAGR during the forecast period owing to a high increase in the number of cancer cases including liver cancer, breast cancer, ovarian cancer, and others in the region. The growth of the regional market is also attributed to a high level of awareness among the patients and the presence of advanced healthcare facilities along with strong regulatory framework & strong reimbursement policies. However, the market of Asia Pacific is expected to expand at a significant growth rate in the coming years owing to the increasing number of patients suffering from cancer, increasing investments by both private & public sectors, and increasing awareness among people regarding the alternatives of drugs in the region.

liposomal doxorubicin market region

Segments

Segments Covered in the Report

The global liposomal doxorubicin market has been segmented on the basis of

Products

  • Myocet
  • Lipodex
  • Doxil/Caelyx
  • Others

Applications

  • Ovarian Cancer
  • Liver Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Endometrial Cancer
  • Breast Cancer
  • Bone Sarcoma
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Lukemia
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co.
  • Cadila Pharmaceuticals
  • Cipla, Inc.
  • SRS Pharmaceuticals Pvt. Ltd.

Competitive Landscape

Key players competing in the global liposomal doxorubicin treatment market include Johnson & Johnson; Sun Pharmaceutical Industries Ltd.; Merck & Co.; Cadila Pharmaceuticals; Cipla, Inc.; and SRS Pharmaceuticals Pvt. Ltd. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally. The first-ever doxil was introduced by Johnson & Johnson.

liposomal doxorubicin market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. liposomal doxorubicin Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. liposomal doxorubicin Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. liposomal doxorubicin Market - Supply Chain
  4.5. Global liposomal doxorubicin Market Forecast
     4.5.1. liposomal doxorubicin Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. liposomal doxorubicin Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. liposomal doxorubicin Market Absolute $ Opportunity
5. Global liposomal doxorubicin Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. liposomal doxorubicin Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global liposomal doxorubicin Demand Share Forecast, 2019-2026
6. North America liposomal doxorubicin Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America liposomal doxorubicin Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America liposomal doxorubicin Demand Share Forecast, 2019-2026
7. Latin America liposomal doxorubicin Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America liposomal doxorubicin Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America liposomal doxorubicin Demand Share Forecast, 2019-2026
8. Europe liposomal doxorubicin Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe liposomal doxorubicin Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe liposomal doxorubicin Demand Share Forecast, 2019-2026
9. Asia Pacific liposomal doxorubicin Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific liposomal doxorubicin Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific liposomal doxorubicin Demand Share Forecast, 2019-2026
10. Middle East & Africa liposomal doxorubicin Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa liposomal doxorubicin Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa liposomal doxorubicin Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global liposomal doxorubicin Market: Market Share Analysis
  11.2. liposomal doxorubicin Distributors and Customers
  11.3. liposomal doxorubicin Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Johnson & Johnson
     11.4.2. Sun Pharmaceutical Industries Ltd.
     11.4.3. Merck & Co.
     11.4.4. Cadila Pharmaceuticals
     11.4.5. Cipla, Inc.
     11.4.6. SRS Pharmaceuticals Pvt. Ltd.

Segments Covered in the Report

The global liposomal doxorubicin market has been segmented on the basis of

Products

  • Myocet
  • Lipodex
  • Doxil/Caelyx
  • Others

Applications

  • Ovarian Cancer
  • Liver Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Endometrial Cancer
  • Breast Cancer
  • Bone Sarcoma
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Lukemia
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co.
  • Cadila Pharmaceuticals
  • Cipla, Inc.
  • SRS Pharmaceuticals Pvt. Ltd.

Key players competing in the global liposomal doxorubicin treatment market include Johnson & Johnson; Sun Pharmaceutical Industries Ltd.; Merck & Co.; Cadila Pharmaceuticals; Cipla, Inc.; and SRS Pharmaceuticals Pvt. Ltd. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally. The first-ever doxil was introduced by Johnson & Johnson.

liposomal doxorubicin market keyplayers

Buy Report